MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40123-026-01366-5

Медицинская библиотека · Ophthalmology and therapy · 2026

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Teo Kelvin Yi Chong, Yoon Young Hee, Honda Shigeru, Park Kyu Hyung, Takahashi Hidenori, Ideta Ryuichi, Sekiryu Tetsuju, Hirata Akira, Obana Akira, Mori Ryusaburo, Chen Shih-Jen, Chee Caroline, Wong James G, Lai Timothy Y Y, Wong Ian, Fung Nick, Lee Won Ki, Terasaki Hiroko, Chen Shih-Chou, Miyatani Takafumi, Iida Tomohiro, Obata Ryo, Machewitz Tobias, Leal Sergio, Cheung Chui Ming Gemmy

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The PLANET study demonstrated that intravitreal aflibercept 2 mg injection (IAI) monotherapy was non-inferior to IAI with rescue photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) at 2 years. This follow-up study assessed the long-term outcomes 6 years after initiation of IAI therapy in the PLANET cohort.

METHODS

This was a non-interventional cohort study of 72 patients with PCV from six international sites who originally completed the PLANET study. Outcomes were assessed during a recall visit at ~6 years from PLANET enrollment. Data collected included best-corrected visual acuity (BCVA), optical coherence tomography, treatment exposure, and adverse events. Patients were treated according to standard of care after exiting from the PLANET study.

RESULTS

Of 72 participants, 32 were randomized to IAI monotherapy and 40 to IAI with rescue PDT. Of those randomized to IAI with rescue PDT, 11 (15.2%) received rescue PDT during the entire study period over 6 years. Mean ± standard deviation (SD) BCVA improved by 14.6 ± 10.3 letters at 2 years but declined to baseline by 6 years (-0.3 ± 21.8 letters). At year 6, 45.8% of eyes had BCVA ≥ 69 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, while 23.6% had < 36 ETDRS letters. Polypoidal lesions were present in 69.4% at year 2 versus 29.2% at year 6. Patients received a mean ± SD of 10.2 ± 2.9 anti-vascular endothelial growth factor (anti-VEGF) injections between years 2-6. Outcomes were better in reimbursed versus non-reimbursed regions. Multivariable analysis showed that younger age and better mean BCVA at year 2 predicted more favorable long-term vision. PDT received at any time was not associated with overall mean BCVA at year 6, although it was associated with a lower risk of ≥ 15-letter loss.

CONCLUSION

At 6 years, initial visual gains from aflibercept therapy were not maintained; however, nearly half of the eyes had BCVA ≥ 69 letters, and a large proportion achieved polypoidal lesion regression.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT002120950.

Для цитирования: Teo Kelvin Yi Chong, Yoon Young Hee, Honda Shigeru, Park Kyu Hyung, Takahashi Hidenori, Ideta Ryuichi, Sekiryu Tetsuju, Hirata Akira, Obana Akira, Mori Ryusaburo, Chen Shih-Jen, Chee Caroline, Wong James G, Lai Timothy Y Y, Wong Ian, Fung Nick, Lee Won Ki, Terasaki Hiroko, Chen Shih-Chou, Miyatani Takafumi, Iida Tomohiro, Obata Ryo, Machewitz Tobias, Leal Sergio, Cheung Chui Ming Gemmy. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.. Ophthalmology and therapy. 2026. DOI: 10.1007/s40123-026-01366-5.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.